Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 110, Issue 11, Pages 2700-2707
Publisher
Springer Nature
Online
2014-05-02
DOI
10.1038/bjc.2014.225
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MicroRNA Expression Profiling of Peripheral Blood Samples Predicts Resistance to First-line Sunitinib in Advanced Renal Cell Carcinoma Patients
- (2015) Angelo Gámez-Pozo et al. NEOPLASIA
- Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma
- (2013) J. Garcia-Donas et al. ANNALS OF ONCOLOGY
- VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib
- (2013) M Scartozzi et al. BRITISH JOURNAL OF CANCER
- Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer
- (2013) R Rosa et al. BRITISH JOURNAL OF CANCER
- Therapy management with sunitinib in patients with metastatic renal cell carcinoma: Key concepts and the impact of clinical biomarkers
- (2012) Daniel Castellano et al. CANCER TREATMENT REVIEWS
- A Phase 2 Trial of Sunitinib in Patients with Advanced Non–clear Cell Renal Cell Carcinoma
- (2012) Nizar M. Tannir et al. EUROPEAN UROLOGY
- Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib
- (2011) Viktor Gruenwald et al. BMC CANCER
- Levels of circulating CD45dimCD34+VEGFR2+ progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors
- (2011) F Farace et al. BRITISH JOURNAL OF CANCER
- Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib
- (2011) Tomoaki Terakawa et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma
- (2010) Brian I. Rini CANCER
- Sunitinib rechallenge in metastatic renal cell carcinoma patients
- (2010) Ivan N. Zama et al. CANCER
- Estimates of cancer incidence and mortality in Europe in 2008
- (2010) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib
- (2010) Camillo Porta et al. KIDNEY INTERNATIONAL
- Soluble Isoforms of Vascular Endothelial Growth Factor Are Predictors of Response to Sunitinib in Metastatic Renal Cell Carcinomas
- (2010) Bernard Paule et al. PLoS One
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started